TruScreen Interim Report

NZX and Media Release 30 January 2018

TruScreen Half Year Report and Interim Financial Statements

TruScreen Limited has provided a copy of its 2018 Interim Report for the six months ended 30
September 2017. The report is available for viewing on the company website
http://truscreen.com/investor-centre/reports-presentations/.


-ENDS-

For more information visit www.truscreen.com or contact:
Martin Dillon
TruScreen Chief Executive Officer
Email: martindillon@truscreen.com
Media Liaison
Jackie Ellis
Email: jackie@ellisandco.co.nz
Phone: +64 27 246 2505

About TruScreen:
TruScreen’s real time cervical cancer
technology utilises a digital wand which is
placed on the surface of the cervix to measure
electrical and optical signals from the
surrounding tissue. A sophisticated proprietary
algorithm framework distinguishes between
normal and abnormal (cancerous and
precancerous) tissue to identify precancerous
change, or cervical intraepithelial neoplasia
(CIN). A Single Use Sensor (SUS) is used for
each patient to protect against cross-infection.

---

1
TruScreen Interim Report 2018
2018 INTERIM
REPORT

2
TruScreen Interim Report 2018
CONTENTS
Our Vision ______________________________________________________________ 03
Progress Against Strategic Goals__________________ 04
Half Year Results Snapshot _____________________________ 05
Chairman and CEO’s Report ____________________________ 06
Interim Financial Statements __________________________ 08
Notes to the Financial Statements _____________________ 13

3
TruScreen Interim Report 2018
Our vision is to provide better
cervical cancer screening to
women around the world and
by doing so, improve the health
and wellbeing of women and
help to save thousands of lives.
TruScreen offers an alternative
approach to cervical screening,
providing real-time, accurate
detection of pre-cancerous and
cancerous cervical cells to help
improve the health and wellbeing of
women around the world.
Cervical cancer is the third most
common cancer in women in the
world. It is different to most cancers
as it has a precancerous phase of
up to 10 years. If diagnosed early,
this precancerous condition can be
treated with almost 100% success,
preventing it from escalating into
cervical cancer.
Most countries in the Western world
have highly developed national
screening programmes that have
significantly reduced the level of
cervical cancer in women. However, a
different screening solution is needed
for women in developing countries
with low resource health economies,
which lack a laboratory infrastructure
and expert diagnostic technicians,
and which account for more than 80%
of deaths.
This is where the TruScreen real time,
low cost and portable diagnostic
device comes into its own. The
TruScreen diagnostic system is
particularly relevant in low resource
health economies as it resolves many
of the ongoing issues associated
with laboratory dependant systems
such as the Pap smear and HPV DNA
screening.
TruScreen manufactures and
owns all rights to the TruScreen®
Cervical Cancer Screening System
which comprises a unique medical
device, disposable single use sensor,
algorithm technology and processes
designed to detect the presence,
at the time of screening, of pre-
cancerous and cancerous tissue on
the cervix.
TruScreen (TRU) is listed on the New
Zealand Stock Exchange’s NZAX
Market, providing investors with an
opportunity to invest in this leading
edge health technology.

4
TruScreen Interim Report 2018
Performance evaluation
of TruScreen2
• Clinical performance evaluation of
TruScreen2 at the Royal Hospital
for Women in Sydney continues to
progress well. Initial results indicate that
TruScreen2 will be a substantially more
accurate screening method than cytology
in developing countries.
Obtain regulatory approval
for TruScreen2 in selected
countries
• Since half year end, received CFDA
approval for TruScreen2 in China and,
as a result, have commenced sales of
TruScreen2 to China.
Gain inclusion in international
Government screening
programmes
• TruScreen’s partners in China are working
at several levels to increase the adoption
of TruScreen in public health programmes
• Validation process for inclusion in India
Government’s public screening process
is underway
• Ministry of Health in Mexico has
commenced evaluation of TruScreen2
as a screening protocol. If successful,
approval would accelerate adoption in
government hospitals
• Approved for reimbursement by major
health insurer in Jordan, a global first
for TruScreen
• The Papua New Guinea Government
has approved a pilot study evaluating
TruScreen as a cervical cancer screening
test in regional and remote locations.
Further establish global
distribution networks
• Signed major new sub-distributor in China
to manage government sales channels
• Established distribution networks for
several other territories outside of China.
Enhance sales of TruScreen2
• Following the December 2017
attainment of CFDA approval, sales
of the new TruScreen2 device to China
have commenced
• Sales growth expected as other regulatory
approvals and health administration
permissions and endorsements are
received; as the pool of TruScreen users
grows with the sale and installation of
TruScreen2 devices; and as early adopters
transition to commercial users across
broader private and public sectors.
PROGRESS AGAINST
STRATEGIC GOALS

5
TruScreen Interim Report 2018
HALF YEAR
RESULTS
SNAPSHOT
For the six months to 30 Sept
TruScreen Limited’s commercial
performance was hampered in
the first half of 2017 due
to delays in gaining CFDA
approval for the TruScreen2
device in China.
This has now been received
and benefits are expected in
the final quarter of the financial
year ending 31 March 2018 and
onwards as initial orders for the
TruScreen2 device are exported
to China and commercialisation
moves ahead in other new
markets. A corresponding
increase in sales of the Single
Use Sensors is expected as
more devices enter the market.
Total revenue was $572,101
made up of sales of $225,896
(HY17: $361,443) and other
income of $346,205, primarily
from grants for Research &
Development. Sales were
down on the previous first half
year (although in line with the
second half of FY17) due to
ongoing product improvements
and validation thereof and the
delays in obtaining Chinese
CFDA approval. In line with
this, net operating cashflow
decreased slightly to $(1.77)
million (HY17: $(747,100)).
Inventory costs rose as
expected, due to increased
production of TruScreen2 in
advance of receiving CFDA
approval and in anticipation
of growing demand from
new markets.
In May 2017 the company
successfully completed an
$897,350 Share Purchase
Plan as part of a larger capital
raising which included a private
placement of $4.09m in March
2017. This contributed to cash
and cash equivalents of $2.63
million as at 30 September
2017, and was the primary
driver for the increased foreign
exchange impact, following
translation from New Zealand
into Australian dollars.
TruScreen reported a Net
Loss of $1.76 million for the
six months, slightly up on the
previous first half year
of $1.68 million.
HY18HY17
Sales$225,896$361,443
Other Income$346,205$461,707
Revenue from Ordinary Activities$572,101$823,150
Net Loss$(1,765,237)$(1,684,133)
Net Assets$13,373,029$12,107,274
Net Operating Cashflow$(1,766,310)$(747,100)
Cash and Cash Equivalents$2,630,624$1,410,327

6
TruScreen Interim Report 2018
CHAIRMAN AND
CEO’S REPORT
We have made good
progress on our
strategic goals for
the FY18 financial
year. Receipt of CFDA
approval for our
TruScreen2 device in
China since the end
of the first half year
has been a major
achievement for
our company.
Our focus remains on those
countries with large populations
of women of screening age,
which have lower levels of
healthcare resources and
access. To date, we have
signed distribution agreements
covering 24 countries with a
combined screening population
of approximately 1 billion
women and we are continuing
to negotiate new agreements.
Whilst all these markets are
important in establishing
TruScreen as the preferred
solution for cervical cancer
screening, our focus is firmly
on the larger of these markets
- China, India and Mexico - and
capitalising on the work done
over the past two years to
gain acceptance.
Within each country, we are
looking to have TruScreen
adopted by both public and
private healthcare providers,
and selected as the preferred
choice for large scale public
screening programmes.
Acceptance and adoption
can take time and is often
dependent on the decisions
and speed of progress of third
parties, such as regulatory
bodies or government
departments, and this timing
can be hard to predict. In
particular, evaluations of the
TruScreen product for use in
public screening programmes
can take many years and
involve multiple in-market trials,
however, each could produce
significant revenue in the future.
China remains the primary
opportunity for our company
and the current focus is on
encouraging the selection
of TruScreen technology for
large screening programs, as
well as increasing adoption
in large provincial hospitals.
A major new sub-distribution
agreement was signed in the
first half to manage government
sales channels in China. The
goal is to have TruScreen
recommended for use in major
central government screening
programs and to be included
in the list of basic medical
equipment for the over 30,000
community healthcare centres
throughout rural China.
Adoption and usage of
TruScreen in prestigious
hospitals in China has
increased. For example, in
the PLA General Hospital over
1000 tests per month are now
being completed, up from
200 in September last year.
We expect this to increase
even further now that CFDA
approval has been obtained and
we can commence supplying
TruScreen2 for commercial use.
After China, India is potentially
the world’s largest screening
market with close to 300
million women of screening
age and the Indian government
is looking to set up public
screening programmes. To be
considered for selection for
this, we need to have TruScreen
validated in-country and have
commenced a collaboration
with the All India Institute of
Medical Science to conduct
this evaluation. We hope to
commence sales to Indian
Central and State Government
institutions in 2018.
In Mexico, the evaluation of
TruScreen by the Ministry
of Health as a screening
protocol has commenced
and if successful, approval
would accelerate adoption
in government hospitals. In
addition, we are participating
in several tenders with the
National Health Secretariat
and State Health Secretariats

7
TruScreen Interim Report 2018
to supply primary screening
in Mexico. We have also
commenced sales to hospitals
controlled by the largest public
health insurer in Mexico,
ISSSTE.
In a global first, TruScreen
has been approved for
reimbursement by a major
health insurer in Jordan. Whilst
Jordan is not a major market,
the attaining of this insurance
rebate is an important step
in breaking down the pricing
barriers that traditional cytology
tests enjoy in larger markets.
We continue to assess
opportunities to expand our
global footprint, while building
our presence in existing
markets. We have a carefully
considered commercial
programme and are currently
rolling this out in other markets
where we have more recently
gained distribution agreements,
including the Middle East,
Europe and Central Asia.
The clinical performance
evaluation of TruScreen2 at
the Royal Hospital for Women
in Sydney is progressing well.
Initial results have confirmed
TruScreen’s advantages over
the Pap smear in developing
countries and indicate
that TruScreen2 will be a
substantially more accurate
screening method than cytology
in those target markets.
TruScreen’s strategy to
restructure the skill set of the
Board has been enacted and
the Board has been refreshed,
with world renowned Professor
Ron Jones and experienced
businessman Mr Chris
Lawrence replacing two long
serving directors. Both Ron
and Chris are enthusiastic
about TruScreen’s future and
about working with their fellow
directors and delivering the
company’s goals for 2018
and beyond.
Outlook
We are at an exciting time
in TruScreen’s evolution as
we move out of the R&D and
validation stage and into the
commercial phase of
our journey.
We have launched our second
generation TruScreen2 device,
established distribution
channels into multiple markets
and our global footprint
continues to grow.
There is growing awareness
and demand from low resource
countries for screening
programmes and the global
market for cervical cancer
screening is forecast to exceed
US$22 billion per year in the
next three years.
The opportunities for TruScreen
look promising and we are
well positioned to continue
to advance the commercial
agenda for our product.
Interest in the TruScreen2
device is strong and while some
approvals are taking longer than
initially anticipated, we expect
to see sales growth once these
approvals are received, and
as early adopters transition
to commercial users across
broader private and public
sectors.
In line with this anticipated
increase in demand, we are
working with key suppliers
to establish our own factory,
significantly increasing our
manufacturing capacity for the
TruScreen2 device.
In addition, TruScreen and
its manufacturing partners
are also working together
to develop plans to have
TruScreen2 assembled in key
offshore markets where this is
a requirement for adoption in
government programs.
These initiatives across our
commercial, manufacturing and
product development programs
set us up for a positive year
in 2018 and we wish to thank
shareholders for their
continued support.
Robert Hunter
Chairman
Martin Dillon
Chief Executive Officer

i
http://www.marketsandmarkets.com/Market-Reports/cervicalcancer-screening-market-%2010110147.html

8
TruScreen Interim Report 2018
INTERIM
UNAUDITED
FINANCIAL
STATEMENTS
FOR THE SIX MONTHS
ENDED 30 SEPTEMBER 2017
Consolidated Statement of Profit
or Loss and Other Comprehensive Income __________________________________________ 09
Consolidated Statement of Financial Position ___________________________________ 10
Consolidated Statement of Changes in Equity ___________________________________ 11
Consolidated Statement of Cash Flows ________________________________________________ 12
Notes to the interim Unaudited Financial Statements _____________________ 13

9
TruScreen Interim Report 2018
CONSOLIDATED STATEMENT OF PROFIT
OR LOSS AND OTHER COMPREHENSIVE INCOME
For the six months ended 30 September 2017
Note
Unaudited for
the six months
ended 30
September 2017
Unaudited for
the six months
ended 30
September 2016
Audited
for the year
ended 31 March
2017
$$$
Revenue from the sale of goods225,896361,443585,388
Other income 3346,205461,707810,202
Changes in inventories288,587209,121408,944
Purchases of inventory(464,115)(459,448)(881,746)
Employee benefit expenses and directors’ fees(670,864)(576,427)(1,174,222)
Administration(185,739)(152,739)(470,394)
Research expenses3(649,171)(564,377)(1,190,910)
Rent(48,444)(47,907)(95,625)
Travel(28,107)(75,931)(156,900)
Marketing & product approvals(159,801)(146,092)(561,811)
Insurance(50,999)(37,724)(87,424)
Shareholder relations & services(3,710)(11,196)(91,999)
Foreign exchange loss3(98,679)(381,432)(68,502)
Amortisation & depreciation3(266,296)(263,131)(528,134)
Finance costs --(37,477)
Loss before income tax(1,765,237)(1,684,133)(3,540,610)
Income tax expense---
Loss for the period after income tax(1,765,237)(1,684,133)(3,540,610)
Other comprehensive income
Item that may be reclassified subsequently to profit or loss
Exchange differences on translating foreign subsidiary operations(42,673)(369,400)(241,728)
Other comprehensive loss for the period(42,673)(369,400)(241,728)
Total comprehensive loss for the period (1,807,910)(2,053,533)(3,782,338)
Basic and Diluted losses (cents per share)(0.9)(1.0)(2.1)
The accompanying notes form part of these financial statements.

10
TruScreen Interim Report 2018
CONSOLIDATED STATEMENT
OF FINANCIAL POSITION
As at 30 September 2017
Note
Unaudited
30 September 2017
Unaudited
30 September 2016
Audited
31 March 2017
$$$
CURRENT ASSETS
Cash and cash equivalents2,630,6241,410,3273,671,571
Trade receivables226,495372,879217,397
Other receivables326,769448,246791,791
Goods and services taxes recoverable97,09072,05969,395
Inventories756,114267,704467,527
Other assets – prepayments75,268220,70177,100
TOTAL CURRENT ASSETS4,112,3602,791,9165,294,781
NON-CURRENT ASSETS
Plant and equipment7,25910,5108,275
Intangible assets9,401,7099,583,4309,738,424
TOTAL NON-CURRENT ASSETS9,408,9689,593,9409,746,699
TOTAL ASSETS13,521,32812,385,85615,041,480
CURRENT LIABILITIES
Trade and other payables36,556198,440644,587
Employee benefits111,74380,14272,605
TOTAL CURRENT LIABILITIES148,299278,582717,192
NET ASSETS13,373,02912,107,27414,324,288
EQUITY
Issued capital622,657,23617,840,46021,800,585
Share Option Reserve172,800187,106172,800
Foreign currency translation reserve(581,977)(666,976)(539,304)
Accumulated losses(8,875,030)(5,253,316)(7,109,793)
Total Equity13,373,02912,107,27414,324,288
The accompanying notes form part of these financial statements.

11
TruScreen Interim Report 2018
CONSOLIDATED STATEMENT
OF CHANGES IN EQUITY
For the year ended 31 March 2017
NoteShare Capital
Accumulated
Losses
Foreign
Currency
Translation
ReserveOption ReserveTotal
$$$$$
Balance at 31 March 2016 (Audited)17,840,460(3,569,183)(297,576)172,71214,146,413
Loss for the period to 30 September 2016-(1,684,133)-(1,684,133)
Other comprehensive income for the period --(369,400)-(369,400)
Total comprehensive loss for the period
(unaudited)
-(1,684,133)(369,400)-(2,053,533)
Transactions with owners
Share based payment---14,39414,394
Total transactions
with owners
---14,39414,394
Balance at 30 September 2016
(Unaudited)
17,840,460(5,253,316)(666,976)187,10612,107,274
Balance at 31 March 2017 (Audited)21,800,585(7,109,793)(539,304)172,80014,324,288
Loss for the period ended
30 September 2017
-(1,765,237)-(1,765,237)
Other comprehensive loss for the period --(42,673)-(42,673)
Total comprehensive loss for the period
(unaudited)
-(1,765,237)(42,673)-(1,807,910)
Transactions with owners
Issue of Ordinary Shares856,651---856,651
Balance at 30 September 2017
(Unaudited)
22,657,236(8,875,030)(581,977)172,80013,373,029
The accompanying notes form part of these financial statements.

12
TruScreen Interim Report 2018
The accompanying notes form part of these financial statements.
CONSOLIDATED STATEMENT
OF CASH FLOWS
For the six months ended 30 September 2017
Note
Unaudited
for the six
months ended
30 September
2017
Unaudited
for the six
months ended
30 September
2016
Audited for the
year ended 31
March 2017
$$$
CASH FLOW FROM OPERATING ACTIVITIES
Cash receipts from customers182,029374,616754,043
Cash paid to suppliers and employees(2,794,335)(2,305,914)(4,436,358)
Cash received from 45% refundable tax offset833,2281,172,0391,126,610
Interest paid--(37,477)
Interest received12,76812,15917,598
Net cash used in operating activities7(1,766,310)(747,100)(2,575,584)
CASH FLOW FROM INVESTING ACTIVITIES
Development of intangible asset
– development costs of upgraded cervical cancer console
-(141,188)(141,188)
Purchase of plant and equipment(1,411)(6,083)(6,355)
Net cash used in investing activities(1,411)(147,271)(147,543)
CASH FLOW FROM FINANCING ACTIVITIES
Proceeds from issue of shares6897,350-4,090,000
Share issue costs(170,576)--
Net cash provided by financing activities726,774-4,090,000
Net (decrease) / increase in cash and cash equivalents(1,040,947)(894,371)1,366,873
Cash and cash equivalents at beginning of period3,671,5712,304,6982,304,698
Cash and cash equivalents at end of period2,630,6241,410,3273,671,571

13
TruScreen Interim Report 2018
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2017
1. REPORTING ENTITY
Truscreen Limited (the “Company”) is a Tier 1
for-profit listed incorporated public company
and is an issuer on the New Zealand Stock
Exchange Alternative Market (“NZAX”).
The Company is a limited liability company
incorporated and domiciled in
New Zealand and registered under the
Companies Act 1993.
Truscreen is a FMC reporting entity for the
purposes of the Financial Reporting Act
2013 and the Financial Markets Conduct
Act 2013.
The Group’s principal activity relates to the
development and manufacture of cancer
detection devices and systems.
The consolidated unaudited interim financial
statements presented for the six months
ended 30 September 2017 are those of
Truscreen Limited and its subsidiaries (the
“Group”). References to “Truscreen” are used
to refer both to the Group and Truscreen
Limited (the “Company”).
These interim financial statements were
authorised for issue by the Board of
Directors on the 12 December 2017.
2. SUMMARY OF
SIGNIFICANT
ACCOUNTING POLICIES
Basis of Preparation
These financial statements are unaudited
and have been prepared in accordance with
New Zealand Generally Accepted Accounting
Practice (“NZ GAAP”) and are in compliance
with NZ IAS 34: Interim Financial Reporting.
The consolidated unaudited interim financial
statements have been prepared in New
Zealand dollars, which is the functional
currency. These financial statements do
not include all the information required for
full financial statements and consequently
should be read in conjunction with the
Group’s financial statements for the year
ended 31 March 2017.
The same accounting policies have been
followed in these financial statements
as were applied in the preparation of the
Group’s audited financial statements for the
year ended 31 March 2017.
Critical Accounting Estimates
and Judgements
When preparing the interim financial
statements, management is required
to make judgements, estimates and
assumptions about carrying values of
assets and liabilities that are not readily
apparent from other sources. The
estimates and associated assumptions
are based on experience and other factors
that are believed to be reasonable under
the circumstances. Actual results may
differ from the estimates, judgements
and assumptions made by management.
Estimates and underlying assumptions are
reviewed on an on-going basis. Revisions to
accounting estimates are recognised in the
period in which the estimate is revised and
in any future periods affected. Information
about significant areas of estimation
uncertainty and critical judgements in
applying accounting policies that have the
most significant effect on the amounts
recognised in the financial statements can
be found in the previous annual report.
Seasonality
Operations are not subject to
seasonal influences.

14
TruScreen Interim Report 2018
4. ADMINSTRATIVE
AND OTHER OPERATING
EXPENSES
Administrative expenses increased in the
six months ended 30 September 2017
compared to the six months ended 30
September 2016 largely due to costs
associated with compliance, marketing and
travel necessary for expansion and ongoing
operations in various regions including
China, Mexico and Europe.
5. OPERATING SEGMENTS
The Group operates in one operating
segment. It owns the rights to the Truscreen
Cervical Cancer Screening System. The
system comprises a medical device and
process designed to detect the presence in
real time of precancerous and cancerous
tissue on the cervix.
The Group is in the process of obtaining
further regulatory approvals. On the granting
of these approvals the Group anticipates
the ability to increase distribution and
revenue. It is anticipated revenues will be
obtained largely from Asia, Europe, Central
and South America. The limited revenues to
date have been obtained in anticipation of
these approvals. These revenues have been
obtained from distributors.
Three major customers each contributed
more than 10% of the Group’s revenue in the
six months to 30 September 2017 (2016:
two customers):
• One customer provided revenue
of $71,170 (34%);
• One customer provided revenue
of $69,095 (33%); and
• Once customer provided revenue
of $50,278 (24%)
No additional disclosure is required in the
interim financial statements as the Group
has one reportable segment.
3. SIGNIFICANT TRANSACTIONS AFFECTING NET LOSS
Significant transactions affecting net loss
The following significant items affecting the unaudited loss for the period are highlighted below because of their size:
Unaudited for the
six months ended
30 September
2017
Unaudited for the
six months ended
30 September
2016
Audited for the
year ended 31
March 2017
$$$
Other income
Research and development grant333,437449,548792,604
Interest 12,76812,15917,598
Total other income346,205461,707810,202
Expense
Amortisation of intangible assets(263,868)(260,961)(523,346)
Foreign exchange loss / unrealized(98,679)(381,432)(68,502)
Research & development costs (649,171)(564,377)(1,190,910)

Ongoing Research & development is being conducted in the following areas:
• Software & firmware improvements incorporated from feedback on prototypes to improve usability;
• Ongoing regulatory and verification processes;
• Changes and improvements to the Electrical Optical Assembly; and
• Further work on developing and testing the algorithm

15
TruScreen Interim Report 2018
6. SHARE CAPITAL
$$
Balance as at 31 March 2016 & 30 September 2016164,766,66617,840,460
Balance as at 31 March 2017190,329,16621,800,585
Share purchase plan 5,609,375897,350
Share issue costs-(40,699)
Balance as at 30 September 2017195,938,54122,657,236
7. RECONCILIATION OF CASH FLOW FROM OPERATING ACTIVITIES
Unaudited
for the six
months ended
30 September
2017
Unaudited
for the six
months ended
30 September
2016
Audited for the
year ended 31
March 2017
$$$
Reconciliation of cash flow from operations with loss after income tax
Loss for the period(1,765,237)(1,684,133)(3,540,610)
Adjusted for:
Share based expense payment – employment expenses-14,39488
Amortisation and depreciation266,295263,131528,134
Exchange difference arising from translating loss items at the date of transaction
and translating cash balances at year end rates
30,174206,227(83,591)
Operating cash flows before working capital changes(1,468,768)(1,200,381)(3,095,979)
(Increase) / Decrease in trade receivables(9,098)13,173547,601
(Increase) / Decrease in other receivables465,022722,491-
(Increase) / Decrease in goods and services taxes recoverable(27,695)(9,453)(6,789)
(Increase) / Decrease in prepayments1,832(54,144)89,457
(Increase) / Decrease in inventory(288,587)(209,122)(408,945)
Increase / (Decrease) in trade and other payables(608,029)(12,819)292,140
(Increase) / Decrease in trade and other payables relating to investing activities--141,188
(Increase) / Decrease in trade and other payables relating to financing activities129,875-(129,875)
Increase / (Decrease) in employee liabilities39,1383,155(4,382)
Net cash from operating activities(1,766,310)(747,100)(2,575,584)

16
TruScreen Interim Report 2018
8. NET TANGIBLE ASSETS PER SHARE
Unaudited
30 September
2017
Unaudited
30 September
2016
Audited
31 March
2017
$$$
Net tangible assets 3,971,3202,523,8444,964,164
Shares on issue at the end of period195,938,541164,766,666190,329,166
Net tangible assets per share (cents per share)2.031.532.41
9. EVENTS SUBSEQUENT TO END OF THE INTERIM PERIOD
There have been no events since 30 September 2017 which would have a material effect on the Group’s interim financial statements
for the 6 months ended 30 September 2017.

17
TruScreen Interim Report 2018
CORPORATE
DIRECTORY
DIRECTORS
Robert Hunter
Sydney, New South Wales
Australia
Ron Jones
Remeura, Auckland
New Zealand
Christopher Horn
Sydney, New South Wales
Australia
Chris Lawrence
St Heliers, Auckland
New Zealand
REGISTERED OFFICE
c/- HLB Mann Judd Limited
Level 6, Equitable House
57 Symonds Street
Grafton
Auckland 1010
New Zealand
AUDITOR
BDO Auckland
Level 4, BDO Centre
4 Graham Street
Auckland 1010
New Zealand
SHARE REGISTRAR
Link Market Services
PO box 91976, Auckland 1142, New Zealand
Level 11 Deloitte Centre,
80 Queen Street, Auckland 1010,
New Zealand
Investor enquiries: 09 375 5998
Investor email: enquiries@linkmarketservices.co.nz
Website: www.linkmarketservices.co.nz

c/- HLB Mann Judd Limited
Level 6, Equitable House
57 Symonds Street
Grafton
Auckland 1010
New Zealand
e: info@TruScreen.com
t: +61 2 9262 4644
www.TruScreen.com